Bristol-Myers Squibb stock closed at USD 62.84 on the NYSE on September 17, 2026, about 8.4% below its 52-week high after a ...

AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal ...

Bristol Myers Squibb acquired the degrader-antibody conjugate from Orum Therapeutics in 2023 for $100 million upfront and the possibility of up to $80 million more in milestones.

Bristol-Myers Squibb (NYSE:BMY) is funding lung cancer screening research in India that targets risks beyond smoking. The ...

Orum Therapeutics shares fell 29.96% after Bristol Myers Squibb halted development of ORM-6151, costing the biotech $80 million in milestone payments.

Bristol-Myers Squibb stock (ISIN US1078421011) is trading close to USD 63.60 on the New York Stock Exchange as of September ...

ASX healthcare stocks are turning to licensing and partnering deals to fund drug development, with Dimerix and Neuren showing ...

Orum Therapeutics' antibody-degrader conjugate platform faces a test as BMS-licensed ORM-6151 nears its Phase 1 primary ...

French biotech Cellectis is abandoning development of its two internal allogeneic CAR-T programs and repositioning itself as an in vivo gene editing company focused initially on cardiovascular disease ...

Bristol Myers Squibb selected Houston for its new, multi-modal manufacturing campus, representing an approximately $2.3 ...

SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has ...

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has appointed Robert Plenge MD, Ph.D., to its Board of Directors, enhancing ...